CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques (Q47217969)

11 January 2018

title

CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques (English)

1 reference

11 January 2018

author name string

Dennis M Klinman

1

1 reference

11 January 2018

Hang Xie

2

1 reference

11 January 2018

Stephen F Little

3

1 reference

11 January 2018

Debra Currie

4

1 reference

11 January 2018

Bruce E Ivins

5

1 reference

11 January 2018

language of work or name

English

0 references

publication date

1 July 2004

1 reference

11 January 2018

published in

Vaccine

1 reference

11 January 2018

volume

22

1 reference

11 January 2018

page(s)

2881-2886

1 reference

11 January 2018

issue

21-22

1 reference

11 January 2018

Bioterrorism: a clear and present danger

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Molecular pathogenesis of Bacillus anthracis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Anthrax vaccine: short-term safety experience in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

CpG oligodeoxynucleotides as vaccine adjuvants in primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

CpG motifs in bacterial DNA trigger direct B-cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

A Toll-like receptor recognizes bacterial DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Therapeutic applications of CpG-containing oligodeoxynucleotides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

DNA activates human immune cells through a CpG sequence-dependent manner

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Mechanism and function of a newly identified CpG DNA motif in human primary B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Combination of microneutralization and avidity assays: Improved diagnosis of recent primary human cytomegalovirus infection in single serum sample of second trimester pregnancy

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

inferred from DOI database lookup

7 January 2021

based on heuristic

Estimation of the avidity of immunoglobulin G for routine diagnosis of chronic Toxoplasma gondii infection in pregnant women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Amplification of antibody production by phosphorothioate oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Type I interferon-mediated stimulation of T cells by CpG DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.020

10.1016/J.VACCINE.2003.12.020

7 January 2021

Identifiers

DOI

1 reference

11 January 2018

PubMed ID

15246624

1 reference

11 January 2018